Core Viewpoint - Travere Therapeutics (TVTX) is anticipated to report a year-over-year increase in earnings and revenues for the quarter ending December 2025, which could significantly influence its stock price depending on the actual results compared to estimates [1][2]. Earnings Expectations - The consensus estimate for quarterly earnings is $0.03 per share, reflecting a year-over-year increase of +104.1% [3]. - Expected revenues are projected to be $142.46 million, representing a 90.5% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 17.07% higher in the last 30 days, indicating a positive reassessment by analysts [4]. - The Most Accurate Estimate for Travere is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +775.01%, suggesting a bullish outlook on the company's earnings [12]. Earnings Surprise Prediction - A positive Earnings ESP is a strong indicator of a potential earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10]. - Stocks with a positive Earnings ESP and a solid Zacks Rank have historically produced a positive surprise nearly 70% of the time [10]. Historical Performance - In the last reported quarter, Travere was expected to post a loss of $0.31 per share but instead reported earnings of $0.28, resulting in a surprise of +190.32% [13]. - Over the past four quarters, the company has exceeded consensus EPS estimates three times [14]. Conclusion - Travere is positioned as a compelling candidate for an earnings beat, but investors should consider other factors that may influence stock performance beyond earnings results [17].

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of VivaVision Biotech (Zhejiang) Co., Ltd.* 維眸生物科技 (浙 江 )股份有限公司 (the "Compan ...

Core Viewpoint - A securities class action lawsuit has been filed against uniQure N.V. for failing to disclose material information regarding its drug candidate AMT-130, leading to significant stock price decline during the class period [1][3][4]. Group 1: Lawsuit Details - Investors have until April 13, 2026, to file lead plaintiff applications if they purchased shares between September 24, 2025, and October 31, 2025 [1]. - The lawsuit alleges that uniQure and certain executives violated federal securities laws by not disclosing critical information during the class period [3]. - The case is identified as Scocco v. uniQure N.V., et al., Case No. 1:26-cv-01124 [5]. Group 2: Company Performance and Impact - During the class period, uniQure indicated a high likelihood of receiving accelerated FDA approval for AMT-130, which was later contradicted by the FDA's assessment [4]. - Following the FDA's announcement on November 3, 2025, uniQure's stock price fell by $33.40, or over 49%, from $67.69 to $34.29 per share [4].

Akebia Therapeutics Conference Summary Company Overview - **Company**: Akebia Therapeutics (NasdaqCM:AKBA) - **Focus**: Improving the lives of individuals affected by kidney disease - **Commercial Products**: - Auryxia: A phosphate binder nearing the end of its life cycle - VAFSEO: A HIF-PHI for treating anemia in chronic kidney disease patients on dialysis, launched about a year ago [4][5] Key Points on VAFSEO - **Initial Uptake**: Strong initial uptake observed post-launch, but faced challenges due to the unique nature of the dialysis market [7][8] - **Market Dynamics**: Dialysis providers control the prescription process, affecting product availability [8] - **Discontinuation Rates**: Higher than expected due to initial hemoglobin dips in patients; efforts are being made to improve patient retention [10][12] - **Dosing Strategy**: Transitioning to a three times weekly (TIW) dosing regimen has shown promising results in reducing discontinuation rates [12][13] - **Patient Access**: By the end of 2025, access to approximately 275,000 patients was achieved [13] - **Long-term Growth**: Data supporting VAFSEO's potential to become the standard of care for anemia in dialysis patients is anticipated [14][24] Clinical Trials and Studies - **VOCAL and VOICE Trials**: - VOCAL: A study comparing VAFSEO to Mircera, expected to show excellent hemoglobin control [20][29] - VOICE: A randomized comparison against Epogen, with results expected early in 2027 [29][31] - **Economic Perspective**: Demonstrating reduced hospitalization costs could enhance the economic proposition for dialysis organizations [31] Pipeline Developments - **Rare Kidney Disease Pipeline**: - Praliciguat: Phase II study initiated for FSGS, targeting rapid progression to end-stage kidney disease [5][40] - AKB-097: A tissue-targeted complement inhibitor, with a basket study planned for IgAN, C3G, and lupus nephritis [40][58] - **Mechanistic Rationale**: Praliciguat stimulates soluble guanylate cyclase, beneficial for podocytes and anti-inflammatory [42][44] - **Patient Focus**: Targeting primary FSGS and genetic mutation-related FSGS while excluding secondary causes [56] Financial Position - **Cash Reserves**: $166 million as of Q3, with at least two years of cash runway [69] Upcoming Catalysts - **Key Events**: - Continued monitoring of VAFSEO's market performance - Progress on Praliciguat and AKB-097 studies - Results from VOCAL and VOICE trials expected within the next 12 months [70][72] Conclusion - **Outlook**: The next 12 months are anticipated to be critical for Akebia, with significant clinical readouts and potential market shifts for VAFSEO and pipeline products [72]

Carillon Tower Advisers, an investment management company, released its fourth-quarter 2025 investor letter “Carillon Eagle Growth & Income Fund”. A copy of the letter can be downloaded here. 2025 marked a positive period for the equity market. The S&P 500 Index returned 2.7% in Q4 and finished the year up 17.9%. The year started with potential disruptions and heightened volatility, while it ended with optimism driven by strong AI investment, clarity in policies, and U.S. Federal Reserve (Fed) interest rate ...

Core Insights - Benitec Biopharma Inc. announced positive results from the BB-301 Phase 1b/2a treatment study, with all four patients in Cohort 1 demonstrating durable responses at the 12-month follow-up [1][4] - The company plans to engage with the FDA in mid-2026 to confirm the pivotal study design for BB-301, which has received Fast Track and Orphan Drug Designations [2][8] - Financial results for the second fiscal quarter ended December 31, 2025, showed total expenses of $13.4 million, an increase from $10.8 million in the same quarter of the previous year [9][10] Clinical Development - All four patients in Cohort 1 were formal responders to BB-301, indicating a durable response at the 12-month follow-up [4] - Patient 1 from Cohort 1 showed continued disease-modifying effects at the 24-month follow-up, with improvements in post-swallow residue and dysphagic symptom burden [6] - Enrollment for Cohort 2 is ongoing, with the first patient treated with a higher dose in Q4 2025, and an interim results update is expected in mid-2026 [7] Responder Analysis - A Responder Analysis was developed to evaluate BB-301 efficacy, including multiple response categories such as patient-reported outcomes and videofluoroscopic swallowing study assessments [3] - The analysis framework combines results from various response categories to assess clinical benefits achieved by each patient [3][11] Financial Performance - Total expenses for the quarter ended December 31, 2025, were $13.4 million, with research and development expenses at $5.8 million, consistent with the previous year [9] - The net loss attributable to shareholders for the quarter was $11.8 million, or $(0.26) per share, unchanged from the previous year [10][14] - As of December 31, 2025, the company had $189 million in cash and cash equivalents [10][13] Corporate Updates - The company is focused on advancing its proprietary "Silence and Replace" DNA-directed RNA interference platform for the treatment of Oculopharyngeal Muscular Dystrophy [16][17] - Benitec has received Orphan Drug Designation from both the EMA and FDA for BB-301, highlighting its potential in treating rare diseases [8][16]

Core Insights - Aprea Therapeutics has expanded its global intellectual property estate with new patents granted in 2025 in Australia and Japan, enhancing protection for its WEE1 and ATR programs, expected to provide exclusivity until 2045 [1][3] - The lead WEE1 inhibitor candidate, APR-1051, is currently in Phase 1 trials, showing early clinical proof of concept, with multiple data readouts anticipated in 2026 [1][3] - Aprea's robust patent strategy aims to secure long-term commercial value and de-risk clinical development by protecting proprietary molecules and therapeutic applications [2][3] WEE1 Program - The WEE1 inhibitor APR-1051 is being evaluated in the ACESOT-1051 Phase 1 clinical trial for advanced/metastatic solid tumors with specific gene alterations [3] - The WEE1 patent portfolio includes one provisional U.S. patent application, two pending U.S. applications, one issued patent in Australia, and 13 pending applications internationally, with core patents expected to provide protection through 2042 [3] ATR Program - The ATR inhibitor ATRN-119 is under evaluation in the ABOYA-119 clinical trial as a monotherapy for patients with advanced solid tumors [4] - The ATR patent estate consists of four issued U.S. patents, one pending U.S. application, one international application, and 21 granted patents, including one issued in Japan in 2025, with existing patents expected to remain in force through 2035-2037 [4] Company Overview - Aprea is focused on developing innovative cancer therapies that exploit cancer-specific vulnerabilities while minimizing damage to healthy cells, aiming to reduce toxicity associated with traditional treatments [6] - The company's lead programs, APR-1051 and ATRN-119, are small-molecule inhibitors targeting solid tumor indications [7]

Core Insights - Oncotelic Therapeutics and Sapu Bioscience have made significant advancements in their global intellectual property portfolio for OT-101, enhancing protection across neurology, oncology, and CNS drug delivery [1][5] Group 1: OT-101 Overview - OT-101 is a clinical-stage therapeutic targeting TGF-β, previously tested in various oncology indications such as glioblastoma and pancreatic cancers, and is now being advanced for CNS applications [2] - The compound has also been investigated for use in Acute Respiratory Distress Syndrome (ARDS) and COVID-19-related inflammatory conditions [2] Group 2: Parkinson's Disease Developments - In Australia, the company has received allowed patent claims for OT-101 specifically for treating Parkinson's Disease, including related sleep disorders like excessive daytime sleepiness and insomnia [3] Group 3: Intracranial Delivery Device - Utility model patents for a device enabling continuous intracranial infusion of pharmaceutical compositions have been granted in China and Germany, effective from April 1, 2025, and extending through 2033 [4] Group 4: Strategic Impact of IP Developments - The new IP developments create an integrated commercialization platform for OT-101, combining therapeutic claims in neurology with delivery-device protection, enhancing its strategic value for future partnerships and commercialization [5][8] Group 5: Patent Wall Strategy - Oncotelic is constructing a multi-layered global "Patent Wall" around OT-101, covering therapeutic use, CNS delivery methods, device administration, dosing regimens, combination therapies, and biomarker-driven patient selection, which complicates replication and strengthens long-term commercial viability [7] Group 6: Company Background - Oncotelic Therapeutics is focused on developing oncology and immunotherapy products, aiming to address high unmet needs in cancer and rare pediatric indications with innovative therapeutic candidates [9][10]

Core Viewpoint - Collegium Pharmaceutical, Inc. is set to report its fourth quarter and full-year 2025 financial results on February 26, 2026, before market opening, followed by a live conference call at 8:00 a.m. ET [1]. Group 1: Financial Reporting - The financial results for Q4 and full-year 2025 will be released before the market opens on February 26, 2026 [1]. - A live conference call and webcast will be held at 8:00 a.m. ET following the financial results announcement [1]. Group 2: Conference Call Information - To access the conference call, participants can dial (877) 407-8037 for U.S. calls or (201) 689-8037 for international calls, referencing the "Collegium Pharmaceutical Q4 2025 Earnings Call" [2]. - An audio webcast will be available on the Company's website, with a replay accessible approximately two hours after the event [2]. Group 3: Company Overview - Collegium Pharmaceutical is focused on becoming a leading, diversified biopharmaceutical company, aiming to improve the lives of individuals with serious medical conditions [3]. - The Company has a strong portfolio in responsible pain management medications and a growing neuropsychiatry business, highlighted by Jornay PM®, a unique treatment for ADHD [3]. - Collegium's strategy includes expanding its commercial portfolio with Jornay PM as the primary growth driver and managing capital deployment in a disciplined manner [3].

MIAMI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2025, after the close of the U.S. financial markets on Thursday, February 26, 2026. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to ...